ReviewDiabetologia2017
Vascular complications in diabetes: old messages, new thoughts.
Review in Diabetologia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- Identification of diagnostic markers for diabetic kidney disease by weighted gene co‑expression network analysis and machine learning.International journal of molecular medicine · 2026Article
- Trans-ethnic estimation and implications of genetic impact on continuous glycemic profiles.Cell discovery · 2026Article
- Clinical characteristics and intensification patterns in subjects with "early" type 2 diabetes in Italy- an analysis from the AMD annals initiative.Acta diabetologica · 2026Article
- An Algorithm for Identifying Microvascular Complications in Type 1 Diabetes in the Clinical Setting: Development and External Validation.Health data science · 2026Article
- The role of AMPK signaling pathway in the pathogenesis of type 2 diabetes mellitus with its complications and related metabolic disorders.Metabolism open · 2025Review
- Metabolic disorders in young people around the world.Diabetologia · 2025Review
- A novel hydrogel loaded with plant exosomes and stem cell exosomes as a new strategy for treating diabetic wounds.Materials today. Bio · 2025Article
- Correlation between key indicators of continuous glucose monitoring and the risk of diabetic foot.World journal of diabetes · 2025Article
- Effect of Early Postoperative Physical Therapy and Educational Program on Wound Recurrence in Diabetic Foot Ulcers: A Randomized Controlled Trial.Journal of clinical medicine · 2025Article
- The risk of type 2-diabetes among persons with intellectual disability: a Danish population-based matched cohort study.Journal of intellectual disability research : JIDR · 2025Article
- Association of the dietary inflammatory index with complicated diabetic kidney disease in people with diabetes mellitus: evidence from NHANES 2009-2018.Acta diabetologica · 2024Article
- LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Ameliorates Endothelial Dysfunction in Diabetic C57BL/6 Mice.Journal of atherosclerosis and thrombosis · 2024Article
- Article
- Uncovering personalized glucose responses and circadian rhythms from multiple wearable biosensors with Bayesian dynamical modeling.Cell reports methods · 2023Article
- Vascular nitric oxide resistance in type 2 diabetes.Cell death & disease · 2023Review
- A study of factors influencing long-term glycemic variability in patients with type 2 diabetes: a structural equation modeling approach.Frontiers in endocrinology · 2023Article
- GLP-1 receptor nitration contributes to loss of brain pericyte function in a mouse model of diabetes.Diabetologia · 2022Article
- Impact of flash glucose monitoring on glycemic control varies with the age and residual β-cell function of patients with type 1 diabetes mellitus.Journal of diabetes investigation · 2022Article
- LCZ696 Protects against Diabetic Cardiomyopathy-Induced Myocardial Inflammation, ER Stress, and Apoptosis through Inhibiting AGEs/NF-κB and PERK/CHOP Signaling Pathways.International journal of molecular sciences · 2022Article
- Protective Effect of High-Intensity Interval Training (HIIT) and Moderate-Intensity Continuous Training (MICT) against Vascular Dysfunction in Hyperglycemic Rats.Journal of nutrition and metabolism · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
In parallel with the growing diabetes pandemic, there is an increasing burden of micro- and macrovascular complications, occurring in the majority of patients. The identification of a number of synergistic accelerators of disease, providing therapeutic pathways, has stabilised the incidence of complications in most western nations. However, the primary instigators of diabetic complications and, thus, prevention strategies, remain elusive. This has necessitated a refocus on natural history studies, where tissue and plasma samples are sequentially taken to determine when and how disease initiates. In addition, recent Phase III trials, wherein the pleiotropic effects of compounds were arguably as beneficial as their glucose-lowering capacity in slowing the progression of complications, have identified knowledge gaps. Recently the influence of other widely recognised pathological pathways, such as mitochondrial production of reactive oxygen species, has been challenged, highlighting the need for a diverse and robust global research effort to ascertain viable therapeutic targets. Technological advances, such as -omics, high-resolution imaging and computational modelling, are providing opportunities for strengthening and re-evaluating research findings. Newer areas such as epigenetics, energetics and the increasing scrutiny of our synergistic inhabitants, the microbiota, also offer novel targets as biomarkers. Ultimately, however, this field requires concerted lobbying to support all facets of diabetes research.
Indexed as
Identifiers
28725914What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.